131i-tenatumomab - a radioimmunoconjugate of tenatumomab, a murine monoclonal antibody targeting the tumor-associated antigen (taa) tenascin-c (tnc), labeled with iodine I 131, with potential antineoplastic activity. The antibody moiety of iodine I 131 tenatumomab binds to tnc, thereby delivering a cytotoxic dose of iodine I 131 specifically to tumors expressing tnc. Tnc, an extracellular matrix protein, is upregulated in a variety of tumor cell types; it plays a key role in invasion, tumor cell proliferation and immune evasion.
Up to date info
Latest research - 131i-tenatumomab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 131i-tenatumomab for any updates.